Anand Mehra bought $1.5M of Aclaris Therapeutics (ACRS)

Executed Nov 19 2024, disclosed Nov 20 2024, 1 day later.

Value, as filed

$1.5M

666,666 sh × $2.25

Executed

Nov 19 2024

the trade date, as filed

Disclosed

Nov 20 2024

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

-37.6%

-17.0% from execution

Over the 21 trading sessions from the disclosed entry session (Nov 20 2024), the stock returned -37.6% (delay-adjusted); from the execution session (Nov 19 2024), -17.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

AM Anand Mehra Director profile →

Anand Mehra (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in ACRS. Across 1 priced purchase filing, the average 21-session return was -17.0% from execution and -37.6% from disclosure (delay-adjusted; derived). The largest single filing was $1.5M of ACRS (666,666 sh × $2.25, as filed), executed Nov 19 2024.

The name

ACRS ACRS ACRS · 2 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→